A phase I study of cis-malonato[(4R,5R)-4,5-bis(aminomethyl)-1,3-dioxolane] platinum(II)in patients with advanced malignancies

Cancer

Volumn 91, Issue 8, 2001, Pages 1549-1556

  Kim, Noe Kyeong ^a   Kim, Tae You ^a   Shin, Sang Goo ^a   Park, Young Iee ^a   Lee, Jung Ae ^a   Cho, Yong Baik ^a   Kim, Key H ^a   Kim, Dae Kee ^a   Heo, Dae Seog ^b   Bang, Yung Jue ^b  

^a Seoul National University   (South Korea)

^b SK Chemicals   (South Korea)

Author keywords

Dose limiting toxicity; Maximum tolerated dose; Pharmacokinetics; Platinum derivative

Indexed keywords

ANTIEMETIC AGENT; EPTAPLATIN; PLATINUM DERIVATIVE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BONE MARROW SUPPRESSION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG URINE LEVEL; FEMALE; HUMAN; LEUKOPENIA; LIVER TOXICITY; MALE; MUCOSA INFLAMMATION; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEINURIA; THROMBOCYTOPENIA; UREMIA; VOMITING;

ADULT; AGED; ANTINEOPLASTIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HALF-LIFE; HUMANS; INFUSIONS, INTRAVENOUS; KIDNEY DISEASES; LEUKOPENIA; LIVER DISEASES; MALE; MALONATES; MIDDLE AGED; NEOPLASMS; ORGANOPLATINUM COMPOUNDS; THROMBOCYTOPENIA;

EID: 0035871359     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/1097-0142(20010415)91:8<1549::AID-CNCR1164>3.0.CO;2-2     Document Type: Article

References (22)

1. Cisplatin-past, present and future
2. Cisplatin: A clinical overview
3. An active drug in the treatment of disseminated gastric cancer
4. Preclinical studies identifying carboplatin as a visible cisplatin alternative
5. Anticancer activity in murine and human tumor cell lines of bis (platinum) complexes incorporating straight-chain aliphatic diamine linker groups
6. In vitro platinum drug chemosensitivity of human cervical squamous cell carcinoma cell lines with intrinsic and acquired resistance to cisplatin
7. Cisplatin/carboplatin cross-resistance in ovarian cancer
8. Synthesis and antitumor activity of a series of [2-substituted-4,5-bis (aminomethyl)-1,3-dioxolane] platinum(II) complexes
9. In vitro antitumor activity of a new platinum complex, cis-malonato[(4R,5R)4,5-bis(aminomethyl)-1,3-dioxolane]platinum(II) (SKI 2053R), against human lung and stomach cancer cell lines
10. Pharmacokinetics and antitumor activity of a new platinum compound, cis-malonato[(4R,5R)-4,5-bis (aminomethyl)-1,3-dioxolane]-platinum(II),as determined by ex vivo pharmacodynamics
11. Antitumor activity of cis-malonato [(4R,5R)-4,5-bis (aminomethyl)-1,3-dioxolane]platinum(II), a new platinum analogue, as an anticancer agent
12. General pharmacology of cis-malonato[(4R,5R)-4,5-bis (aminomethyl)-1,3-dioxolane]-platinum(II) (SKI 2053R)
13. Subacute toxicity of cis-malonato[(4R,5R)-4,5-bis (aminomethyl)-1,3-dioxolane]platinum(II) (SKI 2053R) in beagle dogs
14. Pharmacokinetics of cis-malonato[(4R,5R)-4,5-bis(aminomethyl)-1,3-dioxolane] platinum(II) in rats
15. Pharmacokinetics, tissue distribution, and excretion of cis-malonato[(4R,5R)-4,5-bis (aminomethy)-1,3-dioxolane] platinum(II) in dogs
16. Acute toxicity of cis-malonato[(4R,5R)-4,5-bis(aminomethyl)1,3-dioxolane]- platinum(II) in rats and mice
17. Reporting results of cancer treatment
18. Data analysis by statistical models
19. Cisplatin nephrotoxicity. A review
20. Cisplatin and platinum analogues: Recent advances
21. Phase I clinical trial and pharmacokinetics of carboplatin (NSC 241240) by single monthly 30-minute infusion
22. Clinical kinetics on intact cisplatin and some related species